Background: CD68 is a marker predominantly expressed on monocytes and macrophages and is used to identify tumor-associated macrophages (TAMs). Macrophages home to specific targets in part through the interaction between CD68 and tissue- and organ-specific lectins or selectins. CD68 staining can be combined with HLA-DR to identify M1 macrophages or with CD163 to identify M2 macrophages, macrophage phenotypes with prognostic associations to outcomes in certain cancers.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views.

Recommended Usage: Human FFPE: 2 ug/mL dilution.
For optimal results, antibody should be titrated for each desired application. 

References

Mei, J. et al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis. Oncotarget. 2016; 7(23): 34217-28.

* Conjugate tested on human tissue.